Stock RPTX REPARE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Repare Therapeutics Inc.

Equities

RPTX

US7602731025

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-25 EDT 		5-day change 1st Jan Change
3.41 USD -3.67% Intraday chart for Repare Therapeutics Inc. -6.06% -53.29%
06-12 Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib CI
06-10 Transcript : Repare Therapeutics Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 02:40 PM

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib
AQ
Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib
CI
Transcript : Repare Therapeutics Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 02:40 PM
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion Trial
MT
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
BU
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of Tresr Clinical Trial
CI
Repare Therapeutics : Corporate Presentation
PU
Repare Therapeutics Gets Fast-Track Designation for Cancer Treatment Combo Candidate
MT
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
BU
Repare Therapeutics Inc. Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
CI
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BU
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
BU
Top Premarket Gainers
MT
Repare Therapeutics Shares Rise Premarket Wednesday After Company Swings to Q1 Net Income Amid Higher Revenue
MT
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
BU
Repare Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
DEBIOPHARM AND REPARE THERAPEUTICS ANNOUNCE FIRST PATIENT DOSED IN PHASE 1/1B MYTHIC TRIAL EVALUATING THE SYNTHETIC LETHAL COMBINATION OF WEE1 AND PKMYT1 INHIBITION
AQ
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
BU
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
BU
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1B Mythic Trial Evaluating the Synthetic Lethal Combination of Wee1 and Pkmyt1 Inhibition
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RPTX Stock
  4. News Repare Therapeutics Inc.